File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/B978-0-12-385061-4.00008-8
- Scopus: eid_2-s2.0-78349237728
- PMID: 21081220
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Vascular actions of adipokines. Molecular mechanisms and therapeutic implications
Title | Vascular actions of adipokines. Molecular mechanisms and therapeutic implications |
---|---|
Authors | |
Keywords | Adipokines Adiponectin Adipose tissue Endothelial dysfunction Inflammation Obesity |
Issue Date | 2010 |
Publisher | Academic Press. |
Citation | Advances In Pharmacology, 2010, v. 60 C, p. 230-255 How to Cite? |
Abstract | Adipose tissue is a critical regulator of vascular function, which until recently had been virtually ignored. Almost all blood vessels are surrounded by perivascular adipose tissue, which is actively involved in the maintenance of vascular homeostasis by producing "vasocrine" signals such as adipokines. Adiponectin and adipocyte fatty acid binding protein (A-FABP), both of which are major adipokines predominantly produced in adipose tissue, have recently been shown to be pivotal modulators of vascular function. Adiponectin has multiple beneficial effects on cardiovascular health. It prevents obesity-induced endothelial dysfunction by inducing nitric oxide production, suppressing endothelial cell activation, inhibiting reactive oxygen species and apoptosis, and promoting endothelial cell repair. By contrast, A-FABP plays a detrimental role in vascular dysfunction and atherosclerosis, mainly by acting as a lipid sensor to transmit toxic lipids-induced vascular inflammation through induction of endoplasmic reticulum stress. Decreased production of adiponectin and/or elevated expression of A-FABP are important contributors to the pathogenesis of obesity-induced endothelial dysfunction and cardiovascular disease. This chapter highlights recent advances in both clinical investigations and animal studies promoting the understanding of the roles of adiponectin and A-FABP in the modulation of vascular function, and discusses the possibilities of using these two adipokines as therapeutic targets to design new drugs for preventing vascular disease associated with obesity and diabetes. © 2010 Elsevier Inc. |
Persistent Identifier | http://hdl.handle.net/10722/139498 |
ISSN | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Xu, A | en_HK |
dc.contributor.author | Wang, Y | en_HK |
dc.contributor.author | Lam, KSL | en_HK |
dc.contributor.author | Vanhoutte, PM | en_HK |
dc.date.accessioned | 2011-09-23T05:50:39Z | - |
dc.date.available | 2011-09-23T05:50:39Z | - |
dc.date.issued | 2010 | en_HK |
dc.identifier.citation | Advances In Pharmacology, 2010, v. 60 C, p. 230-255 | en_HK |
dc.identifier.issn | 1054-3589 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/139498 | - |
dc.description.abstract | Adipose tissue is a critical regulator of vascular function, which until recently had been virtually ignored. Almost all blood vessels are surrounded by perivascular adipose tissue, which is actively involved in the maintenance of vascular homeostasis by producing "vasocrine" signals such as adipokines. Adiponectin and adipocyte fatty acid binding protein (A-FABP), both of which are major adipokines predominantly produced in adipose tissue, have recently been shown to be pivotal modulators of vascular function. Adiponectin has multiple beneficial effects on cardiovascular health. It prevents obesity-induced endothelial dysfunction by inducing nitric oxide production, suppressing endothelial cell activation, inhibiting reactive oxygen species and apoptosis, and promoting endothelial cell repair. By contrast, A-FABP plays a detrimental role in vascular dysfunction and atherosclerosis, mainly by acting as a lipid sensor to transmit toxic lipids-induced vascular inflammation through induction of endoplasmic reticulum stress. Decreased production of adiponectin and/or elevated expression of A-FABP are important contributors to the pathogenesis of obesity-induced endothelial dysfunction and cardiovascular disease. This chapter highlights recent advances in both clinical investigations and animal studies promoting the understanding of the roles of adiponectin and A-FABP in the modulation of vascular function, and discusses the possibilities of using these two adipokines as therapeutic targets to design new drugs for preventing vascular disease associated with obesity and diabetes. © 2010 Elsevier Inc. | en_HK |
dc.language | eng | en_US |
dc.publisher | Academic Press. | - |
dc.relation.ispartof | Advances in Pharmacology | en_HK |
dc.subject | Adipokines | en_HK |
dc.subject | Adiponectin | en_HK |
dc.subject | Adipose tissue | en_HK |
dc.subject | Endothelial dysfunction | en_HK |
dc.subject | Inflammation | en_HK |
dc.subject | Obesity | en_HK |
dc.subject.mesh | Adipokines - metabolism - pharmacology | - |
dc.subject.mesh | Animals | - |
dc.subject.mesh | Blood Vessels - drug effects - metabolism | - |
dc.subject.mesh | Humans | - |
dc.title | Vascular actions of adipokines. Molecular mechanisms and therapeutic implications | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Xu, A: amxu@hkucc.hku.hk | en_HK |
dc.identifier.email | Wang, Y: yuwanghk@hku.hk | en_HK |
dc.identifier.email | Lam, KSL: ksllam@hku.hk | en_HK |
dc.identifier.email | Vanhoutte, PM: vanhoutt@hku.hk | en_HK |
dc.identifier.authority | Xu, A=rp00485 | en_HK |
dc.identifier.authority | Wang, Y=rp00239 | en_HK |
dc.identifier.authority | Lam, KSL=rp00343 | en_HK |
dc.identifier.authority | Vanhoutte, PM=rp00238 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/B978-0-12-385061-4.00008-8 | en_HK |
dc.identifier.pmid | 21081220 | - |
dc.identifier.scopus | eid_2-s2.0-78349237728 | en_HK |
dc.identifier.hkuros | 195690 | en_US |
dc.identifier.hkuros | 184652 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-78349237728&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 60 | en_HK |
dc.identifier.issue | C | en_HK |
dc.identifier.spage | 230 | en_HK |
dc.identifier.epage | 255 | en_HK |
dc.publisher.place | United States | en_HK |
dc.identifier.scopusauthorid | Xu, A=7202655409 | en_HK |
dc.identifier.scopusauthorid | Wang, Y=34973733700 | en_HK |
dc.identifier.scopusauthorid | Lam, KSL=8082870600 | en_HK |
dc.identifier.scopusauthorid | Vanhoutte, PM=7202304247 | en_HK |
dc.identifier.issnl | 1054-3589 | - |